Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application:

Listing of Claims:

1. (**Amended**) A safe for injection, low volume formulation of dantrolene <u>sodium</u>, <u>or salts or analogues thereof</u>, for administration to mammals, comprising:

<u>a medicament which includes</u> dantrolene <u>sodium at a concentration in the range of 30 - 80 mg/ml or in the range of 10 - 60 mg/ml; or one or more salts or analogues thereof;</u>

a water-soluble polysorbate;

a compound selected from the group consisting of sorbitol and mannitol; and water as a liquid carrier, said medicament being dissolved or dispersed in said liquid carrier, said medicament being present in a concentration wherein 3 to 150 milliliters of liquid carrier provides approximately 500 milligrams of medicament,

wherein said dantrolene sodium and water are present together as a colloidal dispersion of dantrolene sodium particles in the water,

wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and

wherein the formulation is safe for intravenous administration.

2. (Withdrawn; Canceled)

3. (Amended) The safe for injection, low volume formulation of claim 1, wherein said medicament includes dantrolene in its salt form wherein a counterion to a dantrolene anion is selected from the group consisting of potassium, sodium, ammonium, calcium and magnesium the formulation consists essentially of:

dantrolene sodium at a concentration in the range of 30 - 80 mg/ml or in the range of 10 – 60 mg/ml;

a water-soluble polysorbate;

a compound selected from the group consisting of sorbitol and mannitol: and water as a liquid carrier,

wherein said dantrolene sodium and water are present together as a colloidal dispersion of dantrolene sodium particles in the water,

wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and

wherein the formulation is safe for intravenous administration.

- 5. (Amended) The safe for injection low volume formulation of claim 1, wherein the dantrolene sodium or one or more salts or analogues thereof is the primary modulator of intracellular calcium present in said medicament the formulation.
 6. (Canceled)
- 7. (Canceled).

4. (Withdrawn; Canceled)

- 8. (Canceled).
- 9. (Canceled)
- 10. (Canceled)
- 11. (Canceled)
- 12. (**Amended**) The safe for injection, low volume formulation of claim 1, further comprising a stabilizer polyvinylpyrrolidone (PVP).
- 13. (**Amended**) The safe for injection, low volume formulation of claim 4 12, consisting essentially of: wherein said medicament and said liquid carrier are present together in a solution dantrolene sodium at a concentration in the range of 30 80 mg/ml or in the range of 10 60 mg/ml;

a water-soluble polysorbate;

a compound selected from the group consisting of sorbitol and mannitol:

polyvinylpyrrolidone (PVP); and

water as a liquid carrier,

wherein said dantrolene sodium and water are present together as a colloidal dispersion of dantrolene sodium particles in the water,

wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and

wherein the formulation is safe for intravenous administration.

14. (Canceled)

15. (Withdrawn; Canceled)


16. (Withdrawn; Canceled)

17. (Withdrawn; Canceled)


18. (Canceled)

- 19. (**Amended**) The safe for injection, low volume formulation of claim 1, wherein at least 95% of the dantrolene sodium particles of medicament in said liquid carrier are no more than 0.8 microns in diameter.
- 20. (**Amended**) The safe for injection, low volume formulation of claim 1, wherein at least 95% of the dantrolene sodium particles of medicament in said liquid carrier are no more than 0.45 microns in diameter.
- 21. (**Amended**) The safe for injection, low volume formulation of claim 1, wherein no particles of <u>dantrolene sodium</u> medicament in said liquid carrier are more than 2 microns in diameter.

22. (Amended) The safe for injection, low volume formulation of claim 1, wherein the
compound is mannitol and the formulation comprises comprising no more than 30 milligrams of
mannitol per milligram of dantrolene.
23. (Canceled)
24. (Canceled)
25. (Canceled)
26. (Canceled)
27. (Withdrawn; Canceled)
28. (Withdrawn; Canceled)
29. (Withdrawn Canceled)
30-74. (Canceled)
75. (Withdrawn; Canceled)
76. (Withdrawn; Canceled)



89. (Previously presented) The composition of claim 88 wherein said quantity ranges from 3 - 150 milliliters.
90. (Previously presented) The composition of claim 88 wherein said quantity is 10 milliliters or less.
91. (Previously presented) The composition of claim 88 wherein said quantity is
5 milliliters or less.
92. (Canceled)
93. (Canceled)
94. (Canceled)
95. (Canceled)
96. (Canceled)
97. (Canceled)
98. (Canceled)
99. (Canceled)



111. (Canceled)

112. (Canceled)

113. (Canceled)

114. (Canceled)

115. (Canceled)

116. (Canceled)

117. (New) A safe for injection, low volume liquid formulation of dantrolene sodium for administration to mammals, comprising:

dantrolene sodium at a concentration wherein 3 to 150 milliliters of the liquid formulation provides approximately 500 milligrams of the sodium dantrolene;

110. (Amended) The safe for injection, low volume formulation of claim 1, wherein said

dantrolene sodium medicament is present at 50 mg/ml.

wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and

a compound selected from the group consisting of sorbitol and mannitol; and

water as a liquid carrier, wherein said dantrolene sodium and water are present together

wherein the formulation is safe for intravenous administration.

as a colloidal dispersion of dantrolene sodium particles in the water,

a water-soluble polysorbate;

118. (New) The safe for injection, low volume liquid formulation of dantrolene sodium of claim 117, consisting essentially of:

dantrolene sodium at a concentration wherein 3 to 150 milliliters of the liquid formulation provides approximately 500 milligrams of the sodium dantrolene;

- a water-soluble polysorbate;
- a compound selected from the group consisting of sorbitol and mannitol; and water as a liquid carrier, wherein said dantrolene sodium and water are present together as a colloidal dispersion of dantrolene sodium particles in the water,

wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and

wherein the formulation is safe for intravenous administration.

119. (New) The safe for injection, low volume liquid formulation of dantrolene sodium of claim 117, consisting essentially of:

dantrolene sodium at a concentration wherein 3 to 150 milliliters of the liquid formulation provides approximately 500 milligrams of the sodium dantrolene;

- a water-soluble polysorbate;
- a compound selected from the group consisting of sorbitol and mannitol;

polyvinylpyrrolidone (PVP); and

water as a liquid carrier, wherein said dantrolene sodium and water are present together as a colloidal dispersion of dantrolene sodium particles in the water,

wherein the dantrolene sodium particles are less than about 2 microns in average diameter, and

wherein the formulation is safe for intravenous administration.